Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05410509 · ClinicalTrials.gov registry record · NA
"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"
A NA study of Renal Cell Carcinoma (RCC), sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 4
- Study locations
NCT05410509: Recruiting NA study of Renal Cell Carcinoma (RCC), sponsored by University of Alabama at Birmingham.
NCT05410509 is a NA study of Renal Cell Carcinoma (RCC) that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 25 participants, below the 409-participant average among 12 other Renal Cell Carcinoma (RCC) trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05410509, a NA study of Renal Cell Carcinoma (RCC), is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 4
- Study locations
Study Summary
Multi-center, single arm, prospective trial to estimate safety, feasibility, technical outcomes, and clinical outcomes of percutaneous cryoablation with neo-adjuvant trans-arterial embolization of the tumor in patients with T1b renal cell carcinoma. Continuous safety monitoring will be performed with stopping rules for patient accrual or study continuation.
Conditions Studied
Interventions
- PROCEDURE Trans-arterial embolization (TAE)
Study Locations (4)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- Stanford Cancer Institute - Stanford
Minnesota
- Mayo Clinic - Rochester
Pennsylvania
- Thomas Jefferson Health - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-01-03 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT05410509 shows while recruiting
NCT05410509 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 409-participant average among 12 other Renal Cell Carcinoma (RCC) trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Renal Cell Carcinoma (RCC) appearing as the primary indexed condition, and to 1 intervention - of which Trans-arterial embolization (TAE) is the first listed.
NCT05410509 reports a single indexed study location in Alabama, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05410509 about?
NCT05410509 is a clinical study titled ""Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"". Multi-center, single arm, prospective trial to estimate safety, feasibility, technical outcomes, and clinical outcomes of percutaneous cryoablation with neo-adjuvant trans-arterial embolization of the tumor in patients with T1b renal cell carcinoma. Continuous safety monitoring will be performed wit...
What is the current status of trial NCT05410509?
This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2024-01-03. Estimated completion is 2027-12-31.
What conditions does trial NCT05410509 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma (RCC).
What interventions are being tested in trial NCT05410509?
The interventions under investigation include: Trans-arterial embolization (TAE) (PROCEDURE).
Who is sponsoring clinical trial NCT05410509?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05410509 being conducted?
This trial has 4 study locations across Alabama, California, Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma (RCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05410509's enrollment target sits among peer trials
25 12th of 12 higher than 1 of 12 other Renal Cell Carcinoma (RCC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma (RCC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigation of Lymph Node Biology in Kidney Cancer
RECRUITING · NA
-
ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses
RECRUITING · NA
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
-
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
RECRUITING · Phase 3
-
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI